Sanofi 与 Regeneron 在 Dupixent 成功后扩大合作,签署新抗体联合开发协议
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
Sanofi 与 Regeneron 宣布扩大针对免疫疾病新抗体的合作,Sanofi 支付 10 亿美元首付款,Regeneron 主导研发,Sanofi 负责商业化,利润平分。
文章披露了双方具体的财务条款和研发分工,展示了以成功药物为基础的合作扩展模式。
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Sanofi and Regeneron Pharmaceuticals, the duo behind the hugely successful drug Dupixent, are re-upping their partnership, with the companies announcing Thursday an expanded collaboration on a new series of antibodies for immunological diseases.
As part of the pact, Sanofi is paying Regeneron $1 billion upfront, with possible milestone payments of up to $7 billion more. The deal involves Regeneron taking the lead on research and development, with Sanofi spearheading commercial efforts. Profits on the medicines would be split evenly.
“By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology,” George Yancopoulos, Regeneron’s chief scientific officer, said in a statement.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com